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Abstract 20 
 21 
Secretin (Sct), traditionally a gastrointestinal hormone backed by a century long research, is now 22 
beginning to be recognized also as a neuroactive peptide. Substantiation by recent evidence on 23 
the functional role of Sct in various regions of the brain, especially on its potential 24 
neurosecretion from the posterior pituitary, has revealed Sct’s physiological actions in regulating 25 
water homeostasis. Recent advances in understanding the functional roles of central and 26 
peripheral Sct has been made possible by the development of Sct and Sct receptor (SctR) 27 
knockout animal models which have led to novel approaches in research on the physiology of 28 
this brain-gut peptide. While research on the role of Sct in appetite regulation and fatty acid 29 
metabolism has been initiated recently, its role in glucose homeostasis is unclear. This review 30 
focuses mainly on the metabolic role of Sct by discussing data from the last century and recent 31 
discoveries, with emphasis on the need for revisiting and elucidating the role of Sct in 32 
metabolism and energy homeostasis. 33 
 34 
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1. Introduction 38 
 39 
In a fascinating experiment by Bayliss and Starling in 1902, a loop of jejunum was enervated in 40 
an anaesthetized dog such that it was connected to rest of the body only by blood vessels, and 41 
when acid was infused into the lumen of the isolated jejunum, pancreatic secretion was still 42 
found to occur [7]. This result differed from the existing idea then, that pancreatic secretion was 43 
controlled only by neural vagus stimulation. A chemical substance travelling through blood to 44 
cause this secretion was proposed and the first ever hormone secretin (Sct) was discovered 45 
marking the establishment of the field of Endocrinology. With such great historic importance and 46 
being the longest known hormone, Sct has been researched for a century and a decade now 47 
during which it has been purified, structurally determined, and its receptor identified, cloned and 48 
characterized [19]. Sct is best known for its action in the exocrine pancreas, stimulating secretion 49 
of bicarbonate, water, and electrolytes from pancreatic ductal epithelial cells. It is also associated 50 
with bile release from the liver, and gastric pepsin release and gastric acid inhibition from the 51 
stomach [54]. Recent evidence has established Sct as a neuropeptide while its metabolic role will 52 
be reviewed here in this article. 53 
 54 
2. Secretin and feeding 55 
 56 
2.1 Early studies 57 
 58 
Early evidences that Sct is released after ingestion of a meal had come in the late 1970s and early 59 
1980s. Pelletier et al. found that Sct is released intermittently after a liquid meal in humans and 60 
they proposed that this increase would be sufficient for potentiating bicarbonate release [84]. A 61 
study in 1979 in dogs also reported that plasma immuno reactive Sct levels are significantly 62 
increased after a meat meal [49]. Following this, several other studies have also confirmed the rise 63 
of plasma Sct concentrations after ingestion [26, 43, 56, 70]. At around the same time, studies were 64 
also conducted on effects of Sct in suppressing feeding. Glick et al. in 1971 [40] reported the 65 
effects of CCK and Sct in feeding behavior and concluded that neither of the peptide had any 66 
effect. Two years later, there was another study reporting that, among these two peptides, only 67 
CCK was able to reduce food intake in rats [39]. Since then, there were contradictory reports 68 
regarding the role of Sct in satiety showing that Sct had no effect on feeding behavior in rat [64] 69 
and sheep [25], while Grovum [42] suggested that intravenous infusion of Sct could reduce 70 
appetite in fasted sheep. With these contrasting evidences had come a long halt in studies on role 71 
of Sct in appetite control, while CCK, studied along with Sct in most of these initial reports, is now 72 
one of the most researched peptides for its role in the inhibition of food intake. 73 
 74 
2.2 Secretin a neuropeptide  75 
 76 
In 1981, Charlton et al. [17] and O’Donohue et al. [79] found Sct immuno-reactivities in various 77 
regions of rat and pig brains by radio immuno-assay and high-pressure liquid chromatography. 78 
This was followed by another report in 1984 [92] showing that Sct-like immuno-reactivities are 79 
specifically high in rat hypothalamus and pituitary. Simultaneously, Propst et al. demonstrated 80 
cAMP production by Sct in neuroblastoma–glioma hybrid cells [86] and the same phenomenon 81 
was also shown to occur in cultured mouse brain cells [107], rat brain slices [37], hypothalamic 82 
and hippocampal regions [48], and in rat superior cervical ganglion (SCG) [46]. A study by 83 
Yung et al. [114] in 2001 showed that Sct is localized in somatodendritic area of Purkinje cells 84 
of cerebellar cortex and that it functions as a retrograde messenger to facilitate GABA 85 
transmission from basket cells to Purkinje neurons. This sealed any doubts in the neuroactive 86 
role of Sct. Fuelled by its proposed therapeutic advantage in autism, Sct was then further found 87 
to be localized in cerebral cortex, amygdaloidal complex, hippocampus, hypothalamus, brain 88 
stem, and its possible neuroactive roles in these regions were also discussed [53, 57, 99, 110]. It 89 
was also found that peripheral Sct induced an increase in the Fos-positive neurons in many brain 90 
regions like amygdala (CeA), area postrema (AP), nucleus tractus solitarius (NTS), locus 91 
coeruleus (LC), Barrington's nucleus (Bar), parabrachial nucleus (PBel), and arcuate nucleus 92 
(Arc) which is the centre for regulating feeding behavior. This increase in the Fos expression was 93 
completely abolished by subdiaphragmatic vagotomy indicating that peripheral Sct might 94 
communicate to the brain through the vagal pathway [113]. Incidentally, Sct was also shown to 95 
activate the vagal afferent neurons through its receptor [62], proving that a communication 96 
pathway between the gut and the brain by Sct exists. In the brainstem, Sct and SctR mRNA were 97 
shown to be expressed in AP and NTS [99]. Along with increasing c-Fos expression, Sct could 98 
also activate tyrosine hydroxylase in NTS and depolarize NTS neurons [113]. Sct was also 99 
shown to be endogenously released from the hypothalamic explants when depolarized. This K
+
-100 
induced release was suggested to be associated with voltage-gated sodium and calcium channels 101 
[22]. This growing and compelling evidence on the involvement of Sct in key regions of feeding 102 
centers, including Arc, has led to recent research on the central and peripheral actions of Sct in 103 
modulating food intake [18]. 104 
 105 
2.3 Secretin inhibits food intake 106 
 107 
Cheng et al. [18] have shown that peripheral and central administration of Sct reduces food 108 
intake in fasted mice and this effect was specific to its receptor as the SctR knockout mice did 109 
not express the anorectic effect. SctR belonging to the glucagon receptor family or the class II 110 
family of G protein-coupled receptors has a strong affinity for Sct and lower affinity for 111 
vasoactive intestinal peptide (VIP) [34, 47]. Since VIP binds to SctR at pharmacological doses, 112 
the possibility of cross talk of these peptides on the anorectic role of Sct is minimal. Besides, 113 
VIP has no reported effects on food intake in mice [73] while Sct’s anorectic effect has been 114 
shown clearly to be specific to its receptor with the use of SctR-knockout mice [18]. Sct reduced 115 
food intake at 0.15 nmol (150 pmol) and 1 nmol by intracerebroventricular (i.c.v) injections and 116 
at 5 nmol (about 0.5 mg/kg) by intraperitoneal (i.p) injections, while leptin reduced food intake 117 
at 3 pmol and 60 pmol by i.c.v [71] and 0.12 mg/kg by i.p [6]. CCK-8 exhibits its anorectic 118 
properties at 0.03 nmolby  i.c.v and 1 nmol by i.p [45]. Although higher concentrations of Sct 119 
has been used, it has been ensured that the dosage used is not pharmacological by monitoring 120 
plasma Sct levels 2, 4 and 6 hours after injection. 121 
By immuno-histochemical and insitu hybridization staining techniques, it was shown that Sct 122 
and its receptor are expressed in hypothalamic Arc and para ventricular nucleus (PVN). It was 123 
also shown that Fos-positive cells in these brain regions are dramatically increased after i.p or 124 
i.c.v injection of Sct. Furthermore, peripheral and central Sct also caused a significant increase in 125 
proopiomelanocortin (POMC) mRNA and decrease in the agouti-related protein (AgRP) 126 
transcript levels in Arc as assessed by laser captured microdissection (LCM)-coupled to 127 
quantitative real-time PCR. POMC neurons in the Arc were shown to be colocalized with both 128 
the SctR and Fos-positive neurons in response to i.p and i.c.v Sct. Thus, it was proposed that Sct 129 
activates POMC neurons to bring about its anorectic effect. Indication for the involvement of 130 
melanocortin system was demonstrated by the increased transcript levels of melanocortin-4 131 
receptor (Mc4R) in PVN after i.p and i.c.v Sct, and also by the attenuation of both peripheral and 132 
central Sct-induced anorexia after administration of SHU9119, a Mc4r antagonist, in the PVN. 133 
Peripheral Sct was shown to inhibit food intake without causing conditioned taste aversion 134 
indicating a direct effect of Sct on satiety control [18]. However, whether central Sct also 135 
possesses the same characteristics must be studied, since the conditioned taste aversion caused 136 
by hormones like glucagon like peptide-1 (GLP-1) is different with respect to the site of injection 137 
in brain, indicating distinct receptor population could mediate different functions [111]. In 138 
teleosts, Sct gene has not been found, while other members of same peptide family including 139 
glucagon like peptide (GLP) and glucagon, as well as other peptides such as alpha-MSH and 140 
CCK have also been found to exhibit anorectic actions [109]. The mechanism for Sct-induced 141 
anorexia needs to be investigated further, while it is quite clear that both central and peripheral 142 
Sct utilizes a common melanocortin pathway to exert their effects. It is well known that Sct is 143 
stimulated from the duodenal S cells after a meal and it is highly plausible that this increase in 144 
plasma Sct at the periphery communicates with the brain to inhibit food intake. But the recent 145 
evidence on endogenous release of Sct in hypothalamus [22] implies that a role for central Sct 146 
cannot be ruled out. Mode of communication to the brain by peripheral Sct is likely to be vagal-147 
dependant as Sct and its receptor are localized in the vagal afferent neurons, and central Fos 148 
expression by peripheral Sct is attenuated after vagotomy. A similar reduced anorectic action of 149 
peripheral Sct was also observed after vagotomy indicating the involvement of vagal route [116]. 150 
Although Sct has been shown to cross the blood-brain barrier [5], the possibility of this route for 151 
peripheral Sct to exert its anorectic effect is unlikely since attenuated effects were observed after 152 
vagotomy as mentioned. On the other hand, we found that i.c.v-Sct was able to inhibit food 153 
intake even after vagotomy [116], clearly suggesting a central action of Sct in controlling food 154 
intake. These data pave the way for Sct to be included in the research on an integrated pathway 155 
of nutrient and fluid balance. Circumventricularorgans (CVO) in the brain, especially the 156 
subfornical organ (SFO), are being proposed for integration of ingestion behavior [38, 108]. SFO 157 
in the past is known to be the key centre for modulating drinking behavior, but it is now 158 
beginning to be proposed as a feeding centre as well [95]. Studies of ghrelin and amylin 159 
(orexigenic and anorectic peptide, respectively) have shown that they stimulate different 160 
subpopulation of neurons in the SFO, suggesting that SFO might be the center to influence 161 
hypothalamic regulation of feeding [87]. Sct and its receptor are shown to be expressed in SFO 162 
and Sct also stimulates cFos expression in SFO neurons [21]. Central Sct is recently known to 163 
play an indispensible role in mediating ANGII-stimulated water homeostatic responses in the 164 
brain [58] and now with this new evidence on its anorectic effect, Sct could as well be involved 165 
in an integrated pathway modulating ingestion behavior. 166 
 167 
3. Secretin and Fatty acid metabolism 168 
 169 
Evidences for stimulation of lipolysis by Sct could be dated back to 1969 [91] when Daniel 170 
Rudman and Alejandro E. Del Rio reported that synthetic porcine Sct peptide fragment could 171 
stimulate lipolysis in isolated fat cells from rats. In 1970, two separate reports by Rodbell et al. 172 
and Butcher et al. confirmed that Sct stimulates lipolysis and that Sct increases the adenylcyclase 173 
and cAMP levels in rat fat cells [13, 90]. Since then, there were inconsistent evidences. Sct was 174 
shown to be unable to activate lipolysis in chicken and mouse fat cells [24, 36]. Another report 175 
by Ng TB in 1990 [75] showed that Sct could lead to lipolysis in adipose cells of several 176 
mammalian species including rat, mouse, hamster, guinea pig and rabbit, and that Sct was able to 177 
suppress basal- and insulin-stimulated lipogenesis. Other reports suggested that Sct could not 178 
stimulate in-vitro glycerol release in isolated human adipose cells [10] . It was also reported that 179 
Sct could not stimulate  free fatty acid release from healthy humans  in vivo [89].  With these 180 
contradictory reports, the role of Sct in adipocyte metabolism had not been addressed until a very 181 
recent research by Miegueu et al. [68]. In their studies, Miegueu et al. had not only evaluated the 182 
potential of Sct in stimulating lipolysis, but also found that it could stimulate fatty acid and 183 
glucose uptake in both 3T3 L1 adipocytes and isolated rat adipocytes in vitro. Lipolysis, which 184 
was measured by the amount of glycerol released, had increased in the presence of Sct, while 185 
non-esterified fatty acid (NEFA) accumulation declined in the media with Sct-treated 3T3 L1 186 
cells. When tested for uptake of fatty acid, Sct was shown to significantly stimulate fatty acid 187 
uptake and also expression of genes related to lipid uptake and storage, including fatty acid 188 
binding protein 4 (FABP4), diglyceride acyltransferase-1(DGAT-1), cluster of differentiation 36 189 
(CD36) and caveolin 3 (Cav3). Long-term incubation with Sct resulted in augmentation of the 190 
triglyceride storage mass indicating increased lipid storage. Glucose uptake was also increased 191 
significantly in the presence of Sct along with the gene expression of glucose transporter type 4 192 
(GLUT4). Sct caused an increase in mitochondrial activity, thymidine incorporation and 193 
CCAAT/enhancer-binding protein-beta(C/EBP-) expression. SctR’s expression was also higher 194 
during differentiation, indicating that Sct could function to stimulate proliferation and 195 
differentiation of the cultured adipose cells. But the key finding by Miegueu et al. is that Sct, 196 
while stimulates lipolysis, simultaneously increases lipid uptake thereby enhancing substrate 197 
cycling [68]. VIP , the peptide that interacts with SctR with low affinity, has also been shown to 198 
stimulate lipolysis but its lipolytic effects are mediated specifically by the VPAC2-R subtype [2]. 199 
VIP have been shown to stimulate lipolysis at concentrations from 0.1 nM to 100 nM in isolated 200 
rat adipocyte while Sct could also stimulate spontaneous lipolysis at 0.1 nM in isolated rat 201 
adipocyte in vitro [68]. This indicates that Sct is closely related to the regulation of highly 202 
controlled adipose metabolism which remains to be tested in vivo. 203 
 204 
Metabolic role of Sct in starvation has long been suggested since 1975. Many studies in human 205 
subjects have been conducted and it has been found that circulating plasma Sct levels rose 206 
significantly in fasted subjects [44, 67, 81, 96]. While data from humans were consistent, in dogs 207 
they were contradictory [66, 93]. This rise in plasma Sct was postulated to be related to its 208 
lipolytic property which remains to be proven as the role of Sct in lipolysis in vivo has to be 209 
clarified. The idea that gastric acid, which stimulates Sct for bicarbonate secretion, could 210 
stimulate this increase in Sct levels during starvation was negated by the findings that cimetidine, 211 
a gastric acid inhibitor, could not suppress the increase in plasma Sct level and it was concluded 212 
that factors other than HCl are involved [9, 102]. It was also postulated that increase in plasma 213 
Sct levels after exercise could be due to its lipolytic properties as well [8]. But the lack of strong 214 
in-vivo evidence in the role of Sct in lipolysis has prevented any definitive conclusions in its 215 
metabolic role in fasting.  216 
 217 
Several studies have reported that Sct is released in response to duodenal fatty acid infusion [69, 218 
88] and the length of the fatty acid chain could modulate this response [112]. It was also shown 219 
that sodium oleate could directly stimulate Sct-producing S cells in vitro [16]. Although this 220 
release of Sct is postulated to be associated with pancreatic secretion [94], bicarbonate release 221 
[26] and more recently anorectic signals [18], further research should be done to clarify the 222 
relationship of fat and Sct release. Furthermore, SctR expression was shown to be upregulated in 223 
the human omental adipose tissue of obese individuals [41]. Miegueu et al. reported that there is 224 
a strong positive correlation between SctR expression in human omental adipose tissue and body 225 
mass index, insulin and Apolipoprotein B [68], suggesting a potential role for Sct and its receptor 226 
in the development of obesity which is worth studying. 227 
 228 
Lipolysis and lipogenesis are related to lipid-associated and metabolic disorders including 229 
obesity, diabetes, hyperlipidemia [55]. Recent studies suggest the involvement of lipases 230 
belonging to the lipolytic pathway in tumor proliferation or cancer-associated cachexia [115]  231 
reinforcing the potential therapeutic importance of lipolysis. Although the above listed scarce 232 
findings suggest a connection between Sct with fatty acid metabolism, in fact, the role of Sct in it 233 
is still unclear. The pathway responsible for the lipolytic actions of Sct remains unidentified and 234 
there is no in vivo evidence for Sct’s role in lipolysis yet. As Sct is shown to stimulate both 235 
lipolysis and fatty acid uptake in vitro, it would be interesting to study the modulation of lipid 236 
homeostasis by Sct in vivo. Recent advances indicate the involvement of a central regulation in 237 
mediating peripheral lipid metabolism, associating leptin, ghrelin, GLP-1, neuropeptide Y (NPY) 238 
and melanocortin system [76, 77].Thus with evolving research in lipid metabolism and escalating 239 
evidences on its potential importance in human disorders, there is a need for a detailed research 240 
on the effects of Sct in fatty acid metabolism, especially in in-vivo studies.  241 
 242 
4. Secretin and Insulin/Glucose homeostasis 243 
 244 
Just four years from its discovery, Sct was studied on its therapeutic effect on diabetic patients in 245 
1906. The study was initiated by Moore [72] based on the prior knowledge that pancreas 246 
malfunction was related to diabetes and on the proposal that Sct could stimulate pancreatic 247 
secretion. He found that Sct reduced hyperglycemia in diabetic humans, and his work was 248 
followed by various other studies which failed to reproduce a similar effect [4, 23, 35, 63].They 249 
discredited the proposal stating that the strict carbohydrate-free diet followed in Moore’s study, 250 
rather than Sct treatment, could have brought about the reduction of glucose levels. 251 
 252 
Drupe in 1964 showed that intravenous injections of glucose given along with Sct resulted in a 253 
significant reduction in the half-time of glucose disappearance [28], and this study triggered 254 
more research on the insulinotropic effects of Sct. It was shown again by the same research 255 
group [30] that Sct administration caused an increase in insulin concentration in the portal and 256 
peripheral blood in humans. Subsequent studies were done in dogs and humans to confirm the 257 
release of insulin after Sct administration [11, 105]. The next research question was naturally 258 
whether Sct that is endogenously released at physiological range would have this insulinotropic 259 
effect. Studies conducted in patients with histamine-fast [65] and with intra-duodenal acid 260 
infusion in humans and dogs [78] showed a negative response, while those with either a 261 
duodenal infusion of HCl or betazole-induced release of gastric acid did increase the insulin 262 
levels [20, 29]. Evidences then started coming up showing that the effect of Sct on insulin release 263 
was glucose-dependant [61, 106]. This insulin release by Sct was shown to be from a single pool 264 
of the peptide due to the fact that insulin responses progressively decreased when Sct was 265 
administered in identical pulses [60, 61].  266 
 267 
Plasma Sct levels were found to be raised in fasting type II diabetes subjects [103] and 268 
intravenous injections of crude Sct reduced the glucose levels in these patients [85]. Sct 269 
stimulated exocrine secretion of the pancreas have been shown to be reduced in 270 
streptozotocin(STZ)-induced diabetic rats [80] while Sct-induced amylase secretion was 271 
impaired in men with type I diabetes [97]. Studies were being conducted on Sct-induced insulin 272 
responses in normal, obese and diabetic subjects, in which obese subjects showed higher 273 
response and diabetic subjects had no difference with normal subjects [31, 32]. In 1978, a 274 
contradictory report which concluded that intravenous injection of Sct, in doses that mimicked 275 
the level of endogenous Sct in response to intra-duodenal acid, did not have any effect on 276 
glucose-stimulated insulin release [33]. Since then, there were several inconsistent reports. Sct 277 
was shown to specifically augment glucose-stimulated insulin release as it did not change the 278 
insulin responses to arginine, isoproterenol, tolbutamide and glucagon [59]. In mouse pancreatic 279 
islets cells, Sct potentiated in-vitro glucose-stimulated insulin release [51] and the N-terminal 280 
region of the peptide was shown to be important for this effect [50]. In rats, Sct stimulates insulin 281 
secretion without increasing the blood flow to the islets [14], but simultaneously, several reports 282 
negate such insulinotropic effects. In isolated perfused rat pancreas, irrespective of the glucose 283 
concentrations in the perfusate, Sct failed to stimulate insulin release [83]. Many studies in 284 
humans and dogs suggested that Sct either had no effect or the effect was pharmacological and 285 
not physiological [12, 33, 52, 98]. One of the reasons for the discrepancy in these findings might 286 
be  the accuracy in monitoring Sct levels, which in turn might have affected the conclusions of 287 
the studies. However, the apparent absence or extreme low density of SctRs on islets suggests 288 
that the physiological and pharmacological effects of Sct, if present, may either be through an 289 
indirect pathway or may be mediated by another receptor of secretin family that has a lower 290 
affinity for the peptide [104]. Peptides like GIP and GLP-1 have a potent direct action exhibiting 291 
their incretin effect through specific receptors on islet beta cells [3]. Secretin receptor knockout 292 
model animals could be employed for better understanding of Sct’s effect on islet beta cells. 293 
Central control of insulin secretion could be viewed as an indirect pathway, e.g., leptin and NPY 294 
modulates insulin secretion mainly through receptors in the hypothalamus [74] and NTS [27], 295 
respectively.  Sensing of glucose by brain regions [101] including the hypothalamus, has recently 296 
been shown to trigger insulin release [15, 82] establishing a brain-endocrine pancreatic axis. 297 
There is strong evidence for vagal stimulation of beta cell secretion [100].  Such effects are 298 
brought about at least in part by acetylcholine on beta cells, although a role for VIP, PACAP and 299 
GHRH is also likely [100]. With increasing awareness in the direct and indirect mechanisms of 300 
insulin secretion and with improved techniques such as glucose clamps, a role of Sct in insulin 301 
and glucose homeostasis warrants a revisit and further research. 302 
 303 
6. Conclusion 304 
 305 
Recent evidences on pleiotropic actions of Sct, especially on its role as a neuropeptide, have led 306 
to a revision of the plausible physiological functions of this important peptide. A lot of data on 307 
the metabolic role of Sct from the 60s, 70s and 80s, although contradictory, have been 308 
overlooked and followup studies have not been performed thoroughly. In light of this, it is 309 
noteworthy that Sct’s level in circulation have been shown to increase in both energy rich 310 
(postprandial) and energy deficient (starvation) states and hence Sct should be investigated to 311 
clearly elucidate its role in metabolism and energy homeostasis. With recent studies marking a 312 
rebirth of this research, and with markedly improved techniques and current understanding on 313 
the actions of Sct in brain, along with development of unique resources such as Sct and SctR 314 
knockout animal models, future works in this area will hopefully shed mechanistic insights into 315 
understanding how this unique hormone exerts its metabolic actions via central and/or peripheral 316 
pathways. Metabolic disorders including obesity and diabetes are growing in epidemic 317 
proportions, hence, demand for therapeutics and research on understanding the molecular 318 
mechanisms underlying these disorders are on the rise. Further research pertinent to the 319 
metabolic role of Sct could unveil possible relationships of Sct with some metabolic disorders for 320 
future discovery of therapeutic options for these diseases. 321 
 322 
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 610 
 611 
Figure caption: 612 
Fig. 1.Working model summarizing the anorectic effect of secretin (Sct) 613 
Sct is released from the S cells of the duodenum in response to gastric acid and digested products 614 
of fat or protein entering the duodenum. Gut derived Sct could exert its anorectic effect by the 615 
central melanocortin system through either one or combination of the three different routes. 1 (616 
) Sct released from the gut interacts with the SctR in the vagal afferents and 617 
transmits signals through the vagus to reach the NTS in the brainstem which in turn signals to the 618 
hypothalamus.   2 ( ) Sct released endogenously from the hypothalamus could directly 619 
act on its receptors in the Arc. 3 ( ) Sct released from the gut into the circulation could 620 
pass through the blood brain barrier and activate the Arc neurons. On reaching the Arc, Sct 621 
activates the POMC neurons and inhibits the AgRP neurons. POMC is then cleaved into α-MSH 622 
and it activates the MC4R in the PVN which signals downstream to reduce intake of food. 623 
 624 
Fig. 2.Schematic representation of role of secretin (Sct) in lipid metabolism known  625 
Sct stimulates lipolysis in isolated rat adipocytes, releasing glycerol from the adipose cell 626 
through the activation of adeneyl cyclase and cAMP. Sct stimulates esterification of free fatty 627 
acid (FFA) resulting in their uptake and also stimulates glucose uptake thus bringing about 628 
triglyceride accumulation in isolated cells. ‘?’ in the picture represents the information that are 629 
currently unknown and that have not been researched yet. Clearly very little is known on the 630 
regulation of lipid metabolism by Sct indicating the necessity for more research on the topic.    631 


